Seeking Alpha

A leukemia therapy that Novartis (NVS) bought from the University of Pennsylvania has freed nine...

A leukemia therapy that Novartis (NVS) bought from the University of Pennsylvania has freed nine out of 12 patients of the blood cancer. The treatment works by taking the sufferers' immune cells, reprogramming them to target leukemia cells, and then re-injecting them into the patients. Novartis will call the treatment CTL019.
Comments (1)
  • Hellz
    , contributor
    Comments (170) | Send Message
     
    The real news is the patients in the trial all failed standard treatment
    10 Dec 2012, 08:15 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|